BPC-157 is the peptide most likely to come up if you spend any time on biohacker forums or in the kind of gym where people inject things between sets. It is also the peptide where the gap between the hype and the human evidence is the largest in the entire library.
What it actually is
The full name is Body Protection Compound 157. It is a synthetic 15-amino-acid peptide derived from a partial sequence of a larger protein found in human gastric juice. The discovery was made in the 1990s by a team at the University of Zagreb led by Predrag Sikiric. They were looking for endogenous compounds that protected the gastric lining against ulceration. They found one. They synthesized a fragment of it. And they spent the next two decades publishing studies showing that the fragment did remarkable things in animal models of every kind of injury you could think of.
How it works
Three lines of evidence converge in the rodent literature. The first is angiogenesis. BPC-157 upregulates VEGF receptor 2 expression on endothelial cells, which is the master switch for new blood vessel formation. New blood vessels are how injured tissue gets the oxygen and nutrients it needs to heal. Tendons heal slowly partly because they have terrible blood supply. If BPC-157 can make tendons more vascularized in humans the way it does in rats, that is a meaningful intervention.
The second is growth hormone receptor expression. BPC-157 increases the number of growth hormone receptors on tendon fibroblasts. This means circulating growth hormone has more places to bind, which amplifies the natural anabolic signal at the site of injury without raising systemic growth hormone levels.
The third is the nitric oxide system. BPC-157 modulates nitric oxide signaling in ways that affect smooth muscle tone, gut motility, and blood pressure regulation. The mechanism here is messier and less well characterized, but it shows up consistently across studies. It also seems to interact with dopaminergic and serotonergic systems, which is the basis for the surprising results in models of stroke and addiction recovery.
What the rat studies show
The animal evidence base is unusual in its breadth. Severed Achilles tendons in rats, given subcutaneous BPC-157, healed faster and recovered functional strength sooner than control groups. Medial collateral ligaments transected and given BPC-157 healed in four weeks; the controls had not healed appreciably at four weeks. Stomach ulcers induced by NSAIDs were prevented by pre-treatment. Colitis induced experimentally was reduced. Spinal cord injury models showed motor function recovery. Stroke models showed neuroprotection.
The list goes on. Every time someone in the Zagreb group induced an injury in a rat and gave the rat BPC-157, the rat got better faster. The consistency is striking enough that the conclusion BPC-157 does something in tissue biology is hard to dismiss.
What the human studies do not show
Almost no good human RCTs exist. There is a small case series from a sports medicine clinic reporting accelerated recovery in 12 patients with chronic tendon injuries, but it was uncontrolled. There are case reports from the inflammatory bowel disease literature suggesting symptom improvement in refractory ulcerative colitis. There is a great deal of forum testimony from athletes and weekend warriors.
The translational gap from rats to humans is the central problem in BPC-157 evaluation. Drugs that work in rats often fail in humans for reasons that are hard to predict in advance: different receptor expression patterns, different metabolism, different injury biology. We have no way to know whether BPC-157 is one of those drugs without proper trials.
Real-world use
In practice, people use BPC-157 for tendon and ligament injuries that are not healing on the schedule they want. Subcutaneous injection at 250 to 500 micrograms once or twice daily is the typical dose, often delivered as close to the injury site as possible on the theory that local concentrations matter more than systemic ones. Cycles are usually four to six weeks.
Some users swear by it. Some inject for a month and feel nothing. Without a good biomarker for tissue healing, the absence of effect is hard to distinguish from a slow effect.
The risk side
Long-term safety data does not exist in humans. The animal studies showed no toxicity at doses far above what humans use, but extrapolation is uncertain. Manufacturing varies wildly because there is no GMP source: most BPC-157 in the wild is produced by research-chemical labs whose quality control is whatever they say it is. The World Anti-Doping Agency added BPC-157 to its prohibited list in 2022, which is relevant if you compete in any sanctioned sport.
There is no evidence that BPC-157 causes harm at typical doses. There is also no evidence it does not, in the strict sense that long-term human exposure has not been studied.
The honest closing
If you have a stubborn tendon issue that is not responding to physical therapy, ice, NSAIDs, or PRP, BPC-157 is in the conversation. The mechanism is plausible. The animal evidence is consistent. The risk profile, on what we know, is mild. What you do not get is certainty. You get an educated bet.
See it on you
What you can get a clear picture of is what the kind of recovery and recomposition BPC-157 is reported to support could look like on your frame. PepScan generates a photoreal projection from one photo. Worth seeing the result before you decide whether the bet is worth taking.